The most frequent additional genes that acquire molecular abnormalities in MPN patients are TET2 (22% in PV, 18% in PMF and 16% in ET) and ASXL1 (36% in PMF, 12% in PV and 11% in ET) [8,9]. This evidence concerns the gene TET2 and essential thrombocythemia.